Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.59 |
| ▸ | RAF1 | P04049 | 13/20 | 0.59 |
| ▸ | BRAF | P15056 | 13/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546086 | 0.84 | BRAF (0.65) | RAF1BRAFKDR | |
| SCHEMBL545693 | 0.81 | BRAF (0.68) | RAF1BRAFKDR | |
| SCHEMBL545703 | 0.81 | BRAF (0.68) | RAF1BRAFKDR | |
| SCHEMBL545802 | 0.80 | BRAF (0.62) | MAPK14RAF1BRAFKDR | |
| SCHEMBL546566 | 0.80 | BRAF (0.64) | RAF1BRAFKDR | |
| SCHEMBL545232 | 0.79 | BRAF (0.66) | RAF1BRAFKDR | |
| SCHEMBL546182 | 0.79 | BRAF (0.77) | RAF1BRAFKDR | |
| SCHEMBL461378 | 0.78 | BRAF (0.64) | RAF1BRAFKDR | |
| SCHEMBL345458 | 0.78 | BRAF (0.64) | RAF1BRAFKDR | |
| SCHEMBL546516 | 0.78 | BRAF (0.62) | RAF1BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | MAPK14 278/4885MAPK13 276/4885RAF1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.